{
    "title": "108_s1063",
    "content": "The Act titled the \"Brian Lykins Human Tissue Transplant Safety Act of 2003\" is aimed at overseeing entities involved in activities related to human cell, tissue, or cellular or tissue-based products. It includes an amendment to Section 361 of the Public Health Service Act regarding the control of communicable diseases. The Act, known as the \"Brian Lykins Human Tissue Transplant Safety Act of 2003,\" includes an amendment to Section 361 of the Public Health Service Act regarding the control of communicable diseases. The amendment outlines limitations and definitions for regulations prescribed under different subsections. The amendment to Section 361 of the Public Health Service Act defines the \"qualifying stage\" of a communicable disease and expands the definition of \"State\" to include the District of Columbia. The amendment to Section 361 of the Public Health Service Act includes changes to regulations regarding quarantine circumstances and oversight of entities involved in human cell, tissue, or cellular products. The amendment to Section 361 of the Public Health Service Act defines key terms related to human cell, tissue, or cellular products, including the Commissioner, covered entity, and the products themselves. The amendment to Section 361 of the Public Health Service Act defines key terms related to human cell, tissue, or cellular products, including the Commissioner, covered entity, and the products themselves. A 'cellular or tissue-based product' is defined as human cells, tissues, or cellular or tissue-based products in the regulations. Covered entities must comply with regulations and submit registration and listing information to the Commissioner. The Commissioner may conduct inspections of covered entities to ensure compliance with regulations regarding adverse reactions related to human cell, tissue, or cellular products. Covered entities must report adverse reactions as defined by the Commissioner. The covered entity must report adverse reactions to the Commissioner within 15 days of receiving notification. The Commissioner will develop a reporting mechanism and database for adverse reaction information. The Commissioner will promulgate regulations within 90 days of the Human Tissue Transplant Safety Act of 2003 enactment, including defining adverse reactions and donor eligibility procedures. The Commissioner will establish regulations for donor eligibility screening, good tissue practices, and enforcement to ensure human cell and tissue products are free from disease and maintain integrity during processing and distribution. Enforcement actions will be taken for violations. The Commissioner can issue an order for recall or destruction of human cell, tissue, or product if a violation is found, and covered entities must retain the product until further notice. The Commissioner can order the recall or destruction of human cell, tissue, or product in case of a violation, and covered entities must retain the product until further notice. The Commissioner can order the recall or destruction of human cell, tissue, or product in case of a violation to ensure compliance with regulations. This may include suspending or revoking the registration of the entity. This subsection does not affect the regulation of biological products or drugs under the Federal Food, Drug, and Cosmetic Act. Authorization of appropriations is provided for the implementation of this subsection. SEC. 3. CONFORMING AMENDMENTS. Amends various sections of the Federal Food, Drug, and Cosmetic Act, the Public Health Service Act, and Title 49, United States Code by updating references to \"section 361\" to \"section 361(a)\"."
}